Regardless, our results suggest that the combination of mutant BRAF inhibitors and HSP90 inhibitors is a useful strategy to improve their therapeutic efficacy in the treatment of mutant BRAF colon cancer. Here, HSP90AA1 is linked to colonic neoplasm.